Jason Brown

Today marks the beginning of #ALSAwarenessMonth—a time to come together in support of those affected by amyotrophic lateral sclerosis (#ALS), also known as Lou Gehrig’s disease. While individuals and families impacted by ALS remain at the forefront of our mission year-round, this month offers a meaningful opportunity to unite in celebrating the ALS community: to honor those living with ALS, remember those we’ve lost, and strengthen efforts to advance research and policy change. At QurAlis, we are committed to developing #precisionmedicine therapies aimed at slowing and ultimately stopping this devastating disease. Together, through awareness, advocacy, and continued investment in research, we move closer to new treatments—and one day, a cure. #neurodegenerativediseases #neurologicaldiseases

they start their spreadsheet in A1

Don’t know who gets credit, but well done whoever you are.

@NDFootball 😂

@bcathleticdept This year was tough but wake up. This is a massively positive change.

@jasonpbrown321 Nothing to say? we're a fucking joke

@bcathleticdept Or just DM me because you are blocked like a coward.

I couldn't agree more! The boys showed grit and tenacity in their stunning comeback upset win over #351 New Haven today. #grittynotpretty #winning

@bcathleticdept They are giving the max in the new NIL construct. Maybe you should pony up instead of complaining. That’s the issue. Alumni can supplement but aren’t doing it.

@BFW congratulations on the enormity of your success in the first half.

We are pleased to share that Vikas Sharma, QurAlis' CBO, and Jason Parker Brown, our CFO, are participating at the 2025 Citizens JMP Life Sciences Conference being held today and tomorrow (May 7-8, 2025) in New York. They will present a company overview tomorrow, May 8, 2025 at 2:30pET. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

I repeat that every FDA reviewer and senior staff should be required by law to visit one afflicted patient with every single disease they review (with extra pay even.). Every day should be about the patients.

QurAlis is excited to announce positive topline data from our Phase 1 clinical trial of QRL-101 evaluating biomarkers of #ALS and #epilepsy in healthy volunteers (QRL-101-05; NCT06681441). Results demonstrated that QRL-101 has the potential to provide a therapeutic effect in both diseases. #Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in both sporadic and genetic forms of ALS, with the majority caused by the mis-splicing of the KCNQ2 gene in the pre-mRNA. Kv7 is also a clinically validated target to regulate the hyperexcitable state in epilepsy. Read more in our press release at bit.ly/3FznUzH #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

QurAlis is thrilled to be invited to present at the 43rd Annual J.P. Morgan Healthcare Conference. Our CEO and founder @RoetKasper will present a corporate overview on Monday, January 13, 2025 at 5:30pPT. #JPM25 #precisionmedicine #neurodegenerativediseases #neurologicaldiseases bit.ly/3W5RBxS

Proud to have QurAlis sponsor the Walk to Defeat ALS Boston 2024. Although I will be walking virtually - looking forward to showing support for people living with ALS and their families.

QurAlis Presents! QurAlis' CEO and co-founder @RoetKasper was featured on a panel at the @IamBiotech BIO Investor Forum held this week in San Francisco. The panel, 'Expansion of Neurodegenerative Disease Targets and Pipelines,' moderated by Selina Koch, PhD, executive editor and head of intelligence & research at @BioCentury Inc., discussed the latest advancements in diverse approaches to #neurodegenerativediseases. #precisionmedicine #neurologicaldiseases

QurAlis is proud to sponsor the Northeast ALS Consortium (NEALS) 2024 Annual NEALS Meeting which brings together researchers, clinicians, industry leaders, and individuals with lived #ALS experience to discuss the latest advancements in ALS research and treatment. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases meeting.neals.org

KARXT will be the most important drug ever for schizophrenia. Amazing to see new medicines in mental health.

QurAlis joins the rest of the world today to celebrate inviduals living with #FragileX syndrome (#FXS) and families and friends impacted by FXS, as well as raise awareness as we advance research toward finding effective #precisionmedicine treatments and ultimately a cure. FXS is a rare, genetic #neurologicaldisease that is the leading inherited form of intellectual disability and a known cause of #autism. There are no disease-modifying therapies currently available for FXS. #WorldFragileXDay #NationalFragileXAwarenessDay #NationalFragileXAwarenessMonth

QurAlis wishes all a happy and safe #july4th holiday as we celebrate our nation’s birthday. Happy #independenceday!